Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate

By Curran M.J.   Bihrle W.  

Urology, Vol. 53, Iss. 2, 1999-02 ,pp. : 423-424

Elsevier

Access to resources Recommend Favorite

Prostate-specific membrane antigen: present and future applications

By Chang S.S.   Gaudin P.B.   Reuter V.E.   Heston W.D.W.  

Urology, Vol. 55, Iss. 5, 2000-05 ,pp. : 622-629

Elsevier

Access to resources Recommend Favorite

Comparison of proliferating cell nuclear antigen immunostaining in lymph node metastases and primary prostate adenocarcinoma after neoadjuvant androgen deprivation therapy

By Minardi Daniele   Galosi Andrea   Giannulis Ioannis   Montironi Rodolfo   Polito Mario   Muzzonigro Giovanni  

Scandinavian Journal of Urology and Nephrology, Vol. 38, Iss. 1, 2004-02 ,pp. : 19-25

Informa Healthcare

Access to resources Recommend Favorite

Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer

By Benaim E.A.   Pace C.M.   Lam P.M.   Roehrborn C.G.  

Urology, Vol. 59, Iss. 1, 2002-01 ,pp. : 73-78

Elsevier

Access to resources Recommend Favorite

Reference range for prostate-specific antigen levels after external beam radiation therapy for adenocarcinoma of the prostate

By Geist R.W.  

Urology, Vol. 45, Iss. 6, 1995-06 ,pp. : 1016-1021

Elsevier

Access to resources Recommend Favorite